




RealRate

PHARMACEUTICAL 2026

Adial Pharmaceuticals INC
Rank 94 of 178



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Adial Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Adial Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 80% points. The greatest weakness of Adial Pharmaceuticals INC is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 86% points.

The company's Economic Capital Ratio, given in the ranking table, is 220%, being 9.2% points below the market average of 229%.

Input Variable	Value in 1000 USD
Assets, Current	6,181
Cost of Goods Sold	0
Intangible Assets	2.8
Liabilities, Current	1,397
Liabilities, Non-Current	0
Other Assets	490
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	-178
Other Revenues	0
Property and Equipment	0
Research and Development	2,620
Selling, General and Administrative Expense	5,180

Output Variable	Value in 1000 USD
Assets	6,673
Liabilities	1,397
Expenses	7,799
Revenues	0
Stockholders Equity	5,276
Net Income	-7,977
Comprehensive Net Income	-7,977
BaseVar	8,024
ECR before LimitedLiability	87%
Economic Capital Ratio	220%